AVTX vs NDAQ · P/E 0.0, $51.5M cap vs P/E 41, rev $2.53B
Avalo Therapeutics Inc (AVTX) versus Nasdaq Inc (NDAQ) — a side-by-side from cached financials, not a winner call.
Avalo Therapeutics Inc (AVTX) is a biotechnology company listed on US.
Nasdaq Inc (NDAQ) is a financial data & stock exchanges company listed on US.
Latest reported AVTX revenue for 2025-09-30 was $0. Net income was -$30.6M. AVTX currently screens at market cap $51.5M and trailing P/E 0.0.
Latest reported NDAQ revenue for 2026-06-30 was $2.53B. Net income was $507.0M. Revenue was up 18.5% from 2026-03-31 to 2026-06-30. NDAQ currently screens at market cap $51.71B and trailing P/E 40.8.
AVTX currently screens at market cap $51.5M and trailing P/E 0.0. NDAQ currently screens at market cap $51.71B and trailing P/E 40.8.
Not investment advice. Open the AVTX and NDAQ stock pages for the full models.
Not investment advice.